<DOC>
	<DOCNO>NCT00810238</DOCNO>
	<brief_summary>The purpose clinical trial evaluate feasibility , safety efficacy leave ventricular endocardial injection guide bone marrow-derived cardiopoietic cell ( C-Cure ) set chronic heart failure secondary ischemic cardiomyopathy .</brief_summary>
	<brief_title>C-Cure Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Subject ≥ 18 &lt; 75 year old ; Subject Heart Failure , New York Heart Association ( NYHA ) class II class III LVEF &gt; 15 % ≤ 40 % assessed transthoracic echocardiography ; Subject ischemic heart disease ; Subject identifiable ( transthoracic echocardiography ) area transmural scar within left ventricle ; Subject optimal stable medical therapy 2 month ; Subject willing able undergo ICD implantation , prior receive CCure™ already ICD implant ; Subject agree comply followup evaluation ; Subject inform nature clinical trial agree provision provide write informed consent . Subject treat cellbased therapy ; Subject myocardial revascularization PCI CABG within 2 month prior enrolment ; Subject MI within 2 month prior enrolment ; Subject plan PCI , CABG cardiac surgery ; Subject receive biventricular pacemaker within 6 month prior enrolment ; Subject moderate severe aortic valve heart disease , aortic mitral prosthetic valve ; Subject significant mitral valve insufficiency ( Effective Regurgitant Orifice ( ERO ) &gt; 0.2 cm² ) possibility mitral valve surgery ; Subject leave ventricular thrombus ; Subject LV aneurysma candidate surgical aneurysmectomy ; Subject LV ventricular wall thickness &lt; 5 mm target territory ; Subject proven high grade atrioventricular block sustain ventricular tachyarrhythmias ; Subject hemodynamically significant congenital heart disorder ; Subject clinical evidence infection active malignancy ; Subject know stable chronic kidney dysfunction serum creatinine &gt; 2.5 mg/dL two occasion screen period ; Subject experience severe adverse reaction/allergies contrast agent ; Subject atherosclerosis and/or tortuosity aorta , iliac femoral artery degree , could impede preclude safe retrograde passage delivery catheter , judgment investigator ; Subject chronic immunosuppressive transplant therapy ; Subject autologous allogenic bone marrow peripheral stem cell transplant prior solid organ transplantation ; Subject multisystem disease ; Subject test positive Human Immunodeficiency Virus ( HIV 1 HIV 2 ) , Hepatitis B Virus ( HBV ) , Hepatitis C ( HCV ) and/or syphilis ; Women child bear potential ; Subject life expectancy &lt; 1 year non heart failure related cause ; Subject suffer morbid obesity ( Body Mass Index ( BMI ) &gt; 40 ) ; Subject recent history alcohol drug abuse ; Subject surgical medical condition , judgment investigator might warrant exclusion contraindicate safety reason ; Subject currently participate another trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Cell therapy</keyword>
</DOC>